Category
    Regions
    Category
    Regions
    Reset Showing 1 – 10 of 14
    Patterson Companies Inc. SWOT, Financial and Strategic Analysis Report 2025

    Patterson Companies, Inc. engages in distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Patterson Companies Inc.. Patterson Companies Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Patterson Companies Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Patterson Companies Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Patterson Companies Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Patterson Companies Inc. and all latest updates of the company are provided. The 2025 version of Patterson Companies Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Sep-2025

    $100
    UPTO 50% OFF
    $100
    $100
    UPTO 50% OFF
    Prestige Consumer Healthcare Inc. SWOT, Financial and Strategic Analysis Report 2025

    Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Prestige Consumer Healthcare Inc.. Prestige Consumer Healthcare Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Prestige Consumer Healthcare Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Prestige Consumer Healthcare Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Prestige Consumer Healthcare Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Prestige Consumer Healthcare Inc. and all latest updates of the company are provided. The 2025 version of Prestige Consumer Healthcare Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Owens & Minor Inc. SWOT, Financial and Strategic Analysis Report 2025

    Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Owens & Minor Inc.. Owens & Minor Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Owens & Minor Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Owens & Minor Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Owens & Minor Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Owens & Minor Inc. and all latest updates of the company are provided. The 2025 version of Owens & Minor Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    NAVAMEDIC SWOT, Financial and Strategic Analysis Report 2025

    Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of NAVAMEDIC. NAVAMEDIC business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of NAVAMEDIC are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of NAVAMEDIC , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of NAVAMEDIC including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of NAVAMEDIC and all latest updates of the company are provided. The 2025 version of NAVAMEDIC report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    McKesson Corporation SWOT, Financial and Strategic Analysis Report 2025

    McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of McKesson Corporation. McKesson Corporation business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of McKesson Corporation are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of McKesson Corporation , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of McKesson Corporation including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of McKesson Corporation and all latest updates of the company are provided. The 2025 version of McKesson Corporation report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Henry Schein Inc. SWOT, Financial and Strategic Analysis Report 2025

    Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Henry Schein Inc.. Henry Schein Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Henry Schein Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Henry Schein Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Henry Schein Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Henry Schein Inc. and all latest updates of the company are provided. The 2025 version of Henry Schein Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Great Elm Group Inc. SWOT, Financial and Strategic Analysis Report 2025

    Great Elm Group, Inc. engages in the durable medical equipment and investment management businesses. The company distributes respiratory care equipment, including positive air pressure equipment and supplies, ventilators and oxygen equipment, and replacement parts, as well as provides sleep study services; and rents medical equipment. It also offers investment management services. The company was formerly known as Great Elm Capital Group, Inc. and changed its name to Great Elm Group, Inc. in December 2020. Great Elm Group, Inc. was founded in 1994 and is headquartered in Waltham, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Great Elm Group Inc.. Great Elm Group Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Great Elm Group Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Great Elm Group Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Great Elm Group Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Great Elm Group Inc. and all latest updates of the company are provided. The 2025 version of Great Elm Group Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Galenica AG SWOT, Financial and Strategic Analysis Report 2025

    Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates 520 pharmacies, including 368 owned pharmacies and 152 partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands. This segment also offers medication for treatment of patients at home; launches and distributes a portfolio of consumer health, pharmaceutical, and parapharmaceutical products; and marketing and sale services to partners in the healthcare market. The Logistics & IT segment provides range of specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers logistics and IT services, and master data system for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as complete management solutions for pharmacies. The company was founded in 1927 and is headquartered in Bern, Switzerland. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Galenica AG. Galenica AG business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Galenica AG are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Galenica AG , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Galenica AG including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Galenica AG and all latest updates of the company are provided. The 2025 version of Galenica AG report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Celesio AG SWOT, Financial and Strategic Analysis Report 2025

    McKesson Europe AG provides logistics and other services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division engages in the wholesale of pharmaceutical and other health care products. This division serves its customers through 90 wholesale branches that supply pharmaceutical products to approximately 40,000 pharmacies and hospitals, as well as operates 70 distribution centers in Europe. The Retail Pharmacy division operates approximately 2,000 owned pharmacies and approximately 8,000 members in its brand partnership program. This division also provides outpatient drug, e-commerce, and home care services primarily in Belgium, Ireland, Italy, and the United Kingdom under the Lloyds Pharmacy brand. In addition, this division provides traditional prescription drugs, over-the-counter products, and medical services. It also provides other services for pharmacists, such as the organization and management of pharmacy cooperation programs in the Great Britain, France, Portugal, and Belgium. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG is a subsidiary of McKesson Corporation. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Celesio AG. Celesio AG business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Celesio AG are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Celesio AG , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Celesio AG including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Celesio AG and all latest updates of the company are provided. The 2025 version of Celesio AG report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Cardinal Health Inc. SWOT, Financial and Strategic Analysis Report 2025

    Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Cardinal Health Inc.. Cardinal Health Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Cardinal Health Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Cardinal Health Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Cardinal Health Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Cardinal Health Inc. and all latest updates of the company are provided. The 2025 version of Cardinal Health Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF